have serious clinical implications, as one component of ET treatment is the prevention of thrombosis, which in turn may exacerbate the course of an undiagnosed bleeding disorder or even result in life-threatening hemorrhage. Therefore, the identification of patients with ET who are at increased risk of AVWS would likely facilitate individualization of treatment and improve its outcomes.
The aim of this study was to determine the prevalence of AVWS in patients with ET and to verify whether individuals with and without this bleeding disorder differ in terms of their baseline clinical parameters.
continuous variables, and distributions of discrete variables were compared with the Pearson χ 2 test or Fisher exact test. Power and direction of relationships between the presence of AVWS and demographic and clinical characteristics of patients with ET were determined on the basis of odds ratios (ORs) and their 95% confidence intervals (CIs) calculated using a logistic regression analysis. All calculations were performed with the Statistica 10 package (StatSoft, United States), with the threshold of statistical significance set at a P value of 0.05 or lower. Individuals with concomitant AVWS were diagnosed with ET at a significantly younger age than the remaining patients. Moreover, positive results of the test for AVWS were obtained in significantly younger subjects than the negative results (TABLE 1). A total of 5 subjects (14.7%) were diagnosed with AVWS simultaneously with ET, whereas 13 (38.2%), 9 (26.4%), 3 (8.8%), and 4 patients (11.8%)-within 2, 4, 6, and 8 years from the primary diagnosis.
RESULTS
A median age at diagnosis of ET and a median age at the time of testing for AVWS for the whole study group were 56 and 61 years, respectively. AVWS was detected significantly more often in individuals who were diagnosed with ET at the age of 56 years or younger than in those in whom ET was diagnosed at the age of more than 56 years (30/ Patients with and without concomitant AVWS were compared in terms of their demographic characteristics (sex distribution, age at diagnosis of ET, and age at the time of testing for AVWS) and past medical histories. Moreover, we compared their characteristics at the time of testing for AVWS: clinical activity of ET, prevalence of typical clinical symptoms (including signs of a bleeding disorder), the medications used, and laboratory parameters (complete blood count, coagulation profile, C-reactive protein levels, activity of lactate dehydrogenase, prevalence of JAK2 mutations, and results of specific tests for AVWS: activity of VWF, factor VIII and factor IX, level of VWF:Ag, VWF/VWF:Ag ratio, and VWF:CB).
Statistical analysis Normal distributions of continuous variables were verified with the Kolmogorov-Smirnov test, and the results were presented as arithmetic means, standard deviations, and medians and ranges. Statistical characteristics of discrete variables were presented as numbers and percentages. The t test or Mann-Whitney test was used for intergroup comparisons of DISCUSSION Although the occurrence of AVWS in patients with ET is a well-established phenomenon, the available data on the simultaneous prevalence of these 2 conditions are still inconclusive. According to the literature, from 5% to 30% of patients with ET may develop bleeding disorders of various types. 6 However, most data on the prevalence of AVWS among individuals with ET originate from single case reports or relatively small patient series.
4 Our findings, based on the data of a total of 170 patients, suggest that AVWS may develop even in every fifth patient with ET.
Having a relatively large data set of patients with these 2 conditions (n = 34), we tried to identify potential etiological mechanisms and risk factors for the development of AVWS during the course of ET. According to current knowledge, at least 3 mechanisms may be involved in the pathogenesis of AVWS. In most cases of AVWS, the synthesis and release of VWF are normal, smaller proportion of individuals in remission or with a past or currrent history of hematological treatment. This implies that long-term remission of ET (which can be achieved with an appropriate treatment) and a resultant decrease in the number of circulating platelets may protect against AVWS. This hypothesis is also supported by the fact that participants with concomitant AVWS presented with significantly higher platelet counts than the remaining patients. Importantly, individuals with concomitant AVWS were also characterized by higher erythrocyte counts than the remaining subjects, which suggests the potential involvement of increased shear stress in the etiopathogenesis of this bleeding disorder. Also some ET-specific etiopathogenetic mechanisms of AVWS, such as in vivo platelet activation, 25 should be considered.
Apart from an insight into the etiopathogenesis of AVWS, our study provided several clinically important observations. Firstly, it implied that younger age at the diagnosis of ET may predispose to the development of AVWS, as patients with concomitant AVWS were diagnosed with ET approximately 10 years earlier than the remaining subjects. Importantly, in nearly 80% of the cases (n = 27), clinical and laboratory evidence of AVWS was found within 4 years from diagnosis, and in 5 subjects (14.7%), these 2 conditions were diagnosed simultaneously. Furthermore, as mentioned previously, AVWS was diagnosed significantly less often in patients with a history of past or current hematological treatment or remission of ET (or both). Although the majority of individuals with concomitant AVWS presented with elevated platelet counts, our series included only a small proportion of subjects with ultra-high platelet count (>1000 G/l), as well as a small subset of patients who developed this bleeding disorder despite normal platelet count. This is consistent with literature data showing that clinicallyrelevant AVWS may develop even if the platelet count is much below 1000 G/l. 26 Consequently, preventive measures that should be undertaken in patients with ET, especially those diagnosed with this condition at a relatively younger age, should include: 1) testing for AVWS whenever there is clinical evidence for a bleeding abnormality (irrespective of platelet count); 2) appropriate control of the primary condition; and 3) aiming at stable remission.
In line with the current guidelines, 27 the use of aspirin in ET requires caution, especially if platelet count exceeds 1000 G/l. It is noteworthy that all patients with ET included in this study received aspirin therapy before the diagnosis of AVWS, but only about 45% of them presented with typical signs of a bleeding disorder. Furthermore, we showed that such signs do not necessarily point to the presence of AVWS, as similar symptoms were also observed in approximately 30% of patients with ET and without AVWS. The signs of a bleeding disorder present in patients with ET without concomitant AVWS might reflect impaired and its functional deficiency results from: 1) inactivation with specific and nonspecific autoantibodies 7-11 ; 2) absorption of VWF on the surface of platelets or malignant cells 12-16 ; and 3) loss of high-molecular-weight multimers of VWF due to their exposure to high shear stress and proteolysis.
17-19 Our results and the available evidence regarding the pathophysiology of ET imply that it is the latter mechanism that is likely involved in the pathogenesis of AVWS in patients with ET. The loss of large VWF multimers, resulting from their enhanced proteolysis by the ADAMTS13 cleaving protease, has been previously demonstrated in individuals with ET, and the intensity of this process has been shown to depend on platelet count.
20-24 Importantly, our subset of patients with ET and AVWS included a significantly ET and concomitant signs of bleeding disorders may present with AVWS and should be tested for this condition irrespective of their platelet count.
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platelet function, which typically manifests as a prolonged closure time. Therefore, a platelet aggregation assay is another test that should be considered whenever a patient with a bleeding disorder tests negative for AVWS. Not surprisingly, coagulation tests confirmed that all our patients with AVWS presented with defects of primary hemostasis. 28 In addition, the results of specific tests for AVWS were similar to those typically reported in individuals with this condition, 29 and the values of the most analyzed parameters differed significantly from those recorded in the remaining patients with ET. However, according to the literature, determination of VWF:Ag and FVIII levels alone may be insufficient in some cases, 20,30 and some functional assays (eg, VWF:Rco) should be also performed. [31] [32] [33] Importantly, we have conducted all coagulation tests at least 7 days after discontinuation of platelet aggregation inhibitors to exclude false-positive results, which should be a standard of evaluation for AVWS. 34 While interpreting our findings, potential methodological limitations of the study should be considered, which are primarily related to its retrospective design. Some patients with ET were referred to our center with an already established diagnosis of this condition or due to signs of bleeding disorder, and therefore their past medical histories might have been incomplete. Moreover, it cannot be excluded that because of the potential selection bias related to the fact that we analyzed solely the patients treated at the tertiary center, our findings (especially the data on the prevalence of simultaneous AVWS and ET) cannot be generalized onto the whole population of patients with this myeloproliferative disorder. Owing to the retrospective design, we were also unable to conclude on the cause and effect relationship between the tested associations. Another limitation of our study is that we did not perform a VWF multimer analysis. According to Tiede et al, 35 the sensitivity of routine tests for von Willebrand disease that have been used in our study is relatively low and can be strengthened with the multimer analysis. Consequently, the high incidence of AVWS in our study might still be underestimated. However, even these potential limitations do not diminish the fact that, to the best of our knowledge, the current analysis is the largest study on the simultaneous prevalence of AVWS and ET published to date.
36
To summarize, this study showed that even every fifth patient with ET may develop AVWS. The principal etiopathogenetic mechanism behind AVWS in patients with ET seems to be the proteolytic loss of high-molecular-weight multimers of VWF. However, also a role of increased high shear stress cannot be excluded as a potential predisposing factor. Young age at diagnosis of the primary condition and the lack of its appropriate control constitute potential risk factors for AVWS that should be considered during the management of patients with ET. Individuals with
